{"preliminary_commentary":{"by_channel":{"x_thread":26,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01993810\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"inoperable stage II-IIIB NSCLC","name":"RTOG 1308","nct_id":"NCT01993810","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rtog-1308-nct01993810. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel\\* IV over 1 hour and carboplatin\\* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.\n\nCONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses.","label":"Arm I (photon beam radiation therapy and chemotherapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel\\* and carboplatin\\*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.\n\nCONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses.","label":"Arm II (proton beam radiation therapy and chemotherapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","NRG Oncology"],"completion_date":{"date":"2028-11-30","type":"ESTIMATED"},"conditions":["Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Stage III Non-Small Cell Lung Cancer AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7","Stage IIIB Non-Small Cell Lung Cancer AJCC v7"],"enrollment":{"count":330,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["Imfinzi","Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI-4736","MEDI4736"],"type":"BIOLOGICAL"},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16-213","VP-16","VP-16-213"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"},{"name":"Pemetrexed Disodium","otherNames":["Alimta","LY231514","N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt"],"type":"DRUG"},{"name":"Photon Beam Radiation Therapy","otherNames":[],"type":"RADIATION"},{"name":"Proton Beam Radiation Therapy","otherNames":["PBRT","Proton Radiation Therapy"],"type":"RADIATION"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-06-08","lead_sponsor":"Radiation Therapy Oncology Group","official_title":"Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From registration until death or last follow-up; analysis occurs after 390 deaths have been reported"}],"references":[{"citation":"Ramella S, D'Angelillo RM. Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer. Lancet Oncol. 2020 Jul;21(7):873-875. doi: 10.1016/S1470-2045(20)30246-1. No abstract available.","pmid":"32615102","type":"DERIVED"}],"start_date":{"date":"2014-01-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","url":"https://clinicaltrials.gov/study/NCT01993810"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rtog-1308-nct01993810"}